Clinical trial
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly…
NCT00307008 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00307008 |
|---|---|
| Title | Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population. |
| Official title | An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Streptococcus Pneumoniae Vaccines |
| Intervention type | Biological |
| Interventions | Pneumovax 23™ |
| Enrollment | 1,198 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Mar 27, 2006 |
| Last update posted | Apr 15, 2013 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: